| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 151, 177-191, Copyright © 1997 by American Society for Investigative Pathology
REGULAR ARTICLES |
FA van de Loo, S Kuiper, FH van Enckevort, OJ Arntz and WB van den Berg
Department of Rheumatology, University Hospital Nijmegen, The Netherlands.
Using interleukin (IL)-6-deficient (IL-6(0/0) mice or wild-type mice, we investigated the controversial role of IL-6 in joint inflammation and cartilage pathology during zymosan-induced arthritis (ZIA). Monoarticular arthritis was elicited by injection of zymosan into the right knee joint cavity. Production of IL-1, tumor necrosis factor (TNF), IL-6, and nitric oxide by the inflamed knee was assessed in washouts of joint capsule specimens. Plasma corticosterone was measured using a radioimmunoassay. Proteoglycan synthesis was assessed using [35S]sulfate incorporation into patellas ex vivo. Joint swelling was quantified by joint uptake of circulating 99mTechnetium pertechnetate. Histology was taken to evaluate cellular infiltration and cartilage damage. Zymosan caused a rapid increase in articular IL-1, IL-6, TNF, and NO levels. Except for IL-6, the released amounts and time course of these mediators were comparable in the IL-6-deficient mice and the wild- type mice. Elevated plasma corticosterone levels were measured during the first day of arthritis in both strains. At day 2 of ZIA, joint inflammation (joint swelling and cell exudate) in IL-6-deficient mice was comparable with that in the wild-type mice. The marked suppression of chondrocyte proteoglycan synthesis and proteoglycan degradation were on the average higher in the IL-6-deficient mice. Together this resulted in a more pronounced proteoglycan depletion in the IL-6- deficient mice as compared with the wild-type mice during the first week of arthritis. Injection of recombinant IL-6 into the joint cavity corrected the IL-6 deficiency and significantly reduced cartilage destruction. Inflammation was more chronic in the wild-type mice, and these mice also showed a higher prevalence for osteophyte formation. In ZIA, IL-6 plays a dual role in connective tissue pathology, reducing proteoglycan loss in the acute phase and enhancing osteophyte formation in the chronic phase. The latter could be related to the more severe joint inflammation as seen in the normal (IL-6-producing) animals during the chronic phase of arthritis.
This article has been cited by other articles:
 |
|
 |
|
  H. Kawana, H. Karaki, M. Higashi, M. Miyazaki, F. Hilberg, M. Kitagawa, and K. Harigaya CD44 Suppresses TLR-Mediated Inflammation J. Immunol., March 15, 2008; 180(6): 4235 - 4245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Poree, M. Kypriotou, C. Chadjichristos, G. Beauchef, E. Renard, F. Legendre, M. Melin, S. Gueret, D.-J. Hartmann, F. Mallein-Gerin, et al. Interleukin-6 (IL-6) and/or Soluble IL-6 Receptor Down-regulation of Human Type II Collagen Gene Expression in Articular Chondrocytes Requires a Decrease of Sp1{middle dot}Sp3 Ratio and of the Binding Activity of Both Factors to the COL2A1 Promoter J. Biol. Chem., February 22, 2008; 283(8): 4850 - 4865. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Nissler, D Pohlers, M Huckel, J Simon, R Brauer, and R W Kinne Anti-CD4 monoclonal antibody treatment in acute and early chronic antigen induced arthritis: influence on macrophage activation Ann Rheum Dis, November 1, 2004; 63(11): 1470 - 1477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Strazynski, J. A. Eble, H. Kresse, and E. Schonherr Interleukin (IL)-6 and IL-10 Induce Decorin mRNA in Endothelial Cells, but Interaction with Fibrillar Collagen Is Essential for Its Translation J. Biol. Chem., May 14, 2004; 279(20): 21266 - 21270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Nowell, P. J. Richards, S. Horiuchi, N. Yamamoto, S. Rose-John, N. Topley, A. S. Williams, and S. A. Jones Soluble IL-6 Receptor Governs IL-6 Activity in Experimental Arthritis: Blockade of Arthritis Severity by Soluble Glycoprotein 130 J. Immunol., September 15, 2003; 171(6): 3202 - 3209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Paul, U. Koedel, F. Winkler, B. C. Kieseier, A. Fontana, M. Kopf, H.-P. Hartung, and H.-W. Pfister Lack of IL-6 augments inflammatory response but decreases vascular permeability in bacterial meningitis Brain, August 1, 2003; 126(8): 1873 - 1882. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kagari, H. Doi, and T. Shimozato The Importance of IL-1{beta} and TNF-{alpha}, and the Noninvolvement of IL-6, in the Development of Monoclonal Antibody-Induced Arthritis J. Immunol., August 1, 2002; 169(3): 1459 - 1466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ji, A. Pettit, K. Ohmura, A. Ortiz-Lopez, V. Duchatelle, C. Degott, E. Gravallese, D. Mathis, and C. Benoist Critical Roles for Interleukin 1 and Tumor Necrosis Factor {alpha} in Antibody-induced Arthritis J. Exp. Med., July 1, 2002; 196(1): 77 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Deon, S. Ahmed, K. Tai, N. Scaletta, C. Herrero, I.-H. Lee, A. Krause, and L. B. Ivashkiv Cross-Talk Between IL-1 and IL-6 Signaling Pathways in Rheumatoid Arthritis Synovial Fibroblasts J. Immunol., November 1, 2001; 167(9): 5395 - 5403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Balto, H. Sasaki, and P. Stashenko Interleukin-6 Deficiency Increases Inflammatory Bone Destruction Infect. Immun., February 1, 2001; 69(2): 744 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. K. de Hooge, F. A. J. van de Loo, O. J. Arntz, and W. B. van den Berg Involvement of IL-6, Apart from Its Role in Immunity, in Mediating a Chronic Response during Experimental Arthritis Am. J. Pathol., December 1, 2000; 157(6): 2081 - 2091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. T. Ahmed and L. B. Ivashkiv Inhibition of IL-6 and IL-10 Signaling and Stat Activation by Inflammatory and Stress Pathways J. Immunol., November 1, 2000; 165(9): 5227 - 5237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Schädlich, J. Ermann, M. Biskop, W. Falk, F. Sperling, A. Jüngel, J. Lehmann, F. Emmrich, and U. Sack Anti-inflammatory effects of systemic anti-tumour necrosis factor alpha treatment in human/murine SCID arthritis Ann Rheum Dis, July 1, 1999; 58(7): 428 - 434. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. A. Gadient and P. H. Patterson Leukemia Inhibitory Factor, Interleukin 6, and Other Cytokines Using the GP130 Transducing Receptor: Roles in Inflammation and Injury Stem Cells, May 1, 1999; 17(3): 127 - 137. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Ohshima, Y. Saeki, T. Mima, M. Sasai, K. Nishioka, S. Nomura, M. Kopf, Y. Katada, T. Tanaka, M. Suemura, et al. Interleukin 6 plays a key role in the development of antigen-induced arthritis PNAS, July 7, 1998; 95(14): 8222 - 8226. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
